A regioselective acylation series of methyl α-D-glucopyranoside (
1), methyl 3-
O-benzoyl-4,6-
O-benzylidene-α-D-mannopyranoside (
1A), and methyl 4,6-
O-benzylidene-2-
O-(3,5-dinitrobenzoyl)-α-D-mannopyranoside (
1B) has been carried out by the direct acylation method and afforded the 2,6-di-
O
[...] Read more.
A regioselective acylation series of methyl α-D-glucopyranoside (
1), methyl 3-
O-benzoyl-4,6-
O-benzylidene-α-D-mannopyranoside (
1A), and methyl 4,6-
O-benzylidene-2-
O-(3,5-dinitrobenzoyl)-α-D-mannopyranoside (
1B) has been carried out by the direct acylation method and afforded the 2,6-di-
O-glucopyranoside and 2 or 3-
O-mannopyranoside derivatives in an excellent yield. In order to obtain newer products, the 2,6-di-
O-glucopyranoside derivative was further transformed to a series of 3,4-di-
O-acyl derivatives containing a wide variety of functionalities in a single molecular framework. The structures of the newly synthesized compounds were elucidated on the basis of IR, 1H-NMR, 13C-NMR, 13C-DEPT spectral data, and elemental analysis. These synthesized derivatives were screened for
in vitro antimicrobial activities against ten human pathogenic and five phytopathogenic microorganisms. A number of test compounds showed remarkable antimicrobial activity comparable to, and in some cases even higher than, the standard antibiotics employed. It was observed that methyl 3,4-di-
O-(3-chlorobenzoyl)-2,6-di-
O-hexanoyl-α-D-glucopyranoside (
8) ex-hibited a varied range of MIC from 12.5 μg/disc to 25 μg/disc by the disk diffusion method and 1000 μg/mL to 1250 μg/mL by the broth macrodilution method.
Full article